<?xml version="1.0" encoding="UTF-8"?>
<p>There is general agreement that rheumatic patients treated with non-biologics, as well as biologics other than B-cell-depleting agents (like RTX), do not require prophylactic antiviral therapy.
 <sup>
  <xref rid="bibr10-1759720X20912646" ref-type="bibr">10</xref>,
  <xref rid="bibr11-1759720X20912646" ref-type="bibr">11</xref>
 </sup> These patients should be monitored with ALT, HBsAg or HBV DNA, and treated with antivirals when HBsAg or HBV DNA are detected (
 <xref rid="table2-1759720X20912646" ref-type="table">Table 2</xref>, 
 <xref ref-type="fig" rid="fig2-1759720X20912646">Figure 2</xref>).
 <sup>
  <xref rid="bibr10-1759720X20912646" ref-type="bibr">10</xref>,
  <xref rid="bibr11-1759720X20912646" ref-type="bibr">11</xref>
 </sup> There is also consensus that, for patients with hematologic or oncologic diseases treated with B-cell-depleting agents like RTX, prophylactic antiviral therapy is also necessary.
 <sup>
  <xref rid="bibr10-1759720X20912646" ref-type="bibr">10</xref>,
  <xref rid="bibr11-1759720X20912646" ref-type="bibr">11</xref>
 </sup>
</p>
